Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Role of Genetic Modifiers in Hemoglobinopathies

NCT05799118 is registered in ClinicalTrials.gov with Cyprus Institute of Neurology and Genetics as lead sponsor.

NCT NCT05799118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05799118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Lead sponsor
Cyprus Institute of Neurology and Genetics
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2022
Completion date
September 30, 2027
Enrollment
30,000 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hemoglobinopathies, sickle cell disease, thalassemia alpha, thalassemia, beta